211 related articles for article (PubMed ID: 12567307)
1. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.
Mondy K; Yarasheski K; Powderly WG; Whyte M; Claxton S; DeMarco D; Hoffmann M; Tebas P
Clin Infect Dis; 2003 Feb; 36(4):482-90. PubMed ID: 12567307
[TBL] [Abstract][Full Text] [Related]
2. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
[TBL] [Abstract][Full Text] [Related]
4. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
[TBL] [Abstract][Full Text] [Related]
5. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors.
Tsai MS; Hung CC; Liu WC; Chen KL; Chen MY; Hsieh SM; Sheng WH; Sun HY; Shih TT
J Microbiol Immunol Infect; 2014 Apr; 47(2):109-15. PubMed ID: 23073318
[TBL] [Abstract][Full Text] [Related]
6. Bone disorders in human immunodeficiency virus infection.
Glesby MJ
Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
[TBL] [Abstract][Full Text] [Related]
7. Frailty in HIV infected people: a new risk factor for bone mineral density loss.
Bregigeon S; Galinier A; Zaegel-Faucher O; Cano CE; Obry V; Laroche H; Trijau S; Saout A; Poizot-Martin I
AIDS; 2017 Jul; 31(11):1573-1577. PubMed ID: 28426535
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Bonjoch A; Figueras M; Estany C; Perez-Alvarez N; Rosales J; del Rio L; di Gregorio S; Puig J; Gómez G; Clotet B; Negredo E;
AIDS; 2010 Nov; 24(18):2827-33. PubMed ID: 21045635
[TBL] [Abstract][Full Text] [Related]
9. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
[TBL] [Abstract][Full Text] [Related]
10. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population.
Pinto Neto LF; Ragi-Eis S; Vieira NF; Soprani M; Neves MB; Ribeiro-Rodrigues R; Miranda AE
J Clin Densitom; 2011; 14(4):434-9. PubMed ID: 22051092
[TBL] [Abstract][Full Text] [Related]
11. Low bone mass in human immunodeficiency virus-infected climacteric women receiving antiretroviral therapy: prevalence and associated factors.
Gomes DC; Valadares AL; de Moraes MJ; Lagrutta BB; Pinto-Neto AM; Costa-Paiva L
Menopause; 2015 Feb; 22(2):224-30. PubMed ID: 25003619
[TBL] [Abstract][Full Text] [Related]
12. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
[TBL] [Abstract][Full Text] [Related]
13. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management.
Mazzotta E; Ursini T; Agostinone A; Di Nicola AD; Polilli E; Sozio F; Vadini F; Pieri A; Trave F; De Francesco V; Capasso L; Borderi M; Manzoli L; Viale P; Parruti G
AIDS Patient Care STDS; 2015 Apr; 29(4):169-80. PubMed ID: 25692868
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral abnormalities in persons with HIV infection: signal or noise?
Singh K; Moyle GJ
AIDS Read; 2006 Aug; 16(8):407-10, 413-8. PubMed ID: 16933375
[TBL] [Abstract][Full Text] [Related]
16. Bone Metabolism in Men who Live with HIV Aged 50 years and Over: Impact of Infection Duration.
Caglar B; Durcan E; Karaali R; Balkan II; Kaya SY; Yavuzer H; Konukoglu D; Aygun G; Saltoglu N; Bulut IN; Sonmezoglu K; Kadioglu P; Mete B; Tabak OF
Curr HIV Res; 2024; 22(1):65-71. PubMed ID: 38279729
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of antiretroviral therapy: focus on bone density.
Viganò A; Mora S
Expert Opin Drug Saf; 2004 May; 3(3):199-208. PubMed ID: 15155148
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
Badie BM; Soori T; Kheirandish P; Izadyar S; SeyedAlinagh S; Foroughi M; Rostamian A; Mohraz M
Acta Med Iran; 2011; 49(7):460-7. PubMed ID: 21960080
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine.
Kim HS; Chin BS; Shin HS
J Korean Med Sci; 2013 Jun; 28(6):827-32. PubMed ID: 23772145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
